

Manuscript NO: 89995

Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma

The authors would like to thank the associate editor and all anonymous reviewers for their support and constructive comments on this manuscript. The authors have followed up all the comments carefully and have made every possible effort to clean up all the issues. In the following sections, we provide detailed explanations on modifications we've made in response to the comments raised by the editor and reviewers. The responses are presented respectively.

Reviewer #1:

Although current studies of advanced HCC indicate promising efficiency of TKIs or PD-1 inhibitors, the objective response rate remains unsatisfactory. In this study, the authors evaluated the safety and clinical efficacy of triple therapy in HCC patients with BCLC stage C. The study is well performed and the methods are well described.

1. Please make statement of the IRB.

Response: The statement of the IRB has been uploaded.

2. Manuscript, include the tables should be edited carefully. Some minor language polishing should be revised.

Response: Thanks for the suggestion. We have revised the manuscript carefully.

3. Please edit the reference list according to the journal's guideline.

Response: We have edited the reference list according to the journal's guideline.